MGX

Metagenomi is a preclinical genome-editing platform with no approved product and no product revenue — its $25.2M FY2025 top line is collaboration income, and it just fell 51.8% YoY (from $52.3M in FY2024 and $44.8M in FY2023). That is the opposite of the durable, growing revenue the platform story needs: the collaboration base is shrinking while operating losses widen. Net loss hit -$87.9M on a -348.5% net margin and a -380.9% operating margin, and R&D alone ($94.4M) dwarfs revenue nearly 4x. The accumulated deficit is now $310.9M, and management explicitly warns it 'expect[s] to continue to incur significant expenses and increasing operating losses for the foreseeable future' and will 'need substantial additional funding.'

The balance sheet turns this from a slow burn into a near-term financing crisis. Cash of $41.7M against FY2025 operating cash burn of -$88.9M is well under a year of runway — roughly two quarters. The company has pre-loaded the dilution: a $250M S-3 shelf effective March 2025 plus a $75M Jefferies ATM, none of which had been tapped as of year-end. With 37.6M shares and a $47.4M market cap, funding even one year of burn via equity at $1.26 implies punishing dilution to existing holders. The reported $159M stockholders' equity and healthy 0.39x liabilities/equity look reassuring, but that equity is being consumed at ~$88M/year and will erode fast absent a raise.